Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen regulatory affairs director

Executive Summary

Former FDA Office of Cellular, Tissues & Gene Therapies Acting Director Philip Noguchi, MD, joins Amgen. Noguchi will be regulatory affairs director, responsible for the company's regulatory and clinical development policy. Also joining Amgen's Washington D.C. office is former Baxter VP-Government Affairs & Public Policy Jonathon Spear. Spear will be VP-public policy and will work to define strategic public policy options...

You may also be interested in...

CBER cell therapies office director

FDA names former Intronn COO Edward Otto, PhD, director of the Center for Biologics Evaluation & Research Office of Cellular, Tissue & Gene Therapies, effective Nov. 14. Deputy Director Joyce Frey-Vasconcells, PhD, has served as acting director of CBER's cell therapies office since May after Acting Director Phil Noguchi, MD, moved temporarily to the Office of Orphan Products Development. Noguchi left FDA at the end of August to join Amgen (1"The Pink Sheet" Sept. 27, 2004, In Brief)...

More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode

Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.

Merck & Co. Will Manufacture J&J Vaccine, Other COVID-19 Medicines Under BARDA Deal

Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts